Oncologic Imaging Book with CME/SA-CME Credit

Course Directors: Christine Menias, MD and Kumar Sandrasegaran, MD


This book offers 25 AMA Category 1 Credits™ and 25 American Board of Radiology©, MOC Part II, Self-Assessment CME (SA-CME) following completion of an online test. Soft bound book; 360 pages; 50 chapters.


Module 1 — Chest Imaging — 2.5 SA-CME Credits
Module 2 — Gastrointestinal Imaging — 2.5 SA-CME Credits
Module 3 — Musculoskeletal Imaging — 2.5 SA-CME Credits
Module 4 — Gynecology — 2.5 SA-CME Credits
Module 5 — Neuroradiology — 2.5 SA-CME Credits
Module 6 — Pediatric Imaging — 2.5 SA-CME Credits
Module 7 — Urinary Imaging — 2.5 SA-CME Credits
Module 8 — Breast Imaging — 2.5 SA-CME Credits
Module 9 — General Radiology — 2.5 SA-CME Credits
Module 10 — Vascular and/or Interventional Radiology — 2.5 SA-CME Credits

Target Audience:
This course is intended for all professionals involved in radiology with a particular emphasis on practicing radiologists, and trainees in radiology. The Categorical Course “Oncologic Imaging: From Diagnosis to Cure” is specifically designed to deal with patients who have suspected or confirmed cancer, before and after treatment.

Statement of Need:
Oncologic imaging is a substantial part of a radiologists’ daily workload. It is important for radiologists to understand what the clinician needs from a radiology report in the diagnosis and staging of cancer. Following treatment, normally expected post-therapy appearances needs to be distinguished from treatment-related complications and tumor recurrence. Newer imaging techniques can help with more accurate and earlier evaluation of tumor response. This course covers in breadth and depth the field of oncologic imaging, in a wide range of subspecialties, including neuroradiology, musculoskeletal radiology, thoracic radiology, breast radiology, pediatric radiology, gastrointestinal radiology, genitourinary radiology, and interventional radiology

Goals and Objectives:
After completing this course, the learner should be able to:
  1. Diagnose and stage important cancers.
  2. Give a differential diagnosis, when necessary, and suggest the best management strategy.
  3. Apply practice-based strategies for optimizing patient outcomes.
  4. Describe systems barriers to improving diagnoses and patient outcomes.
  5. Articulate differential diagnoses and suggest the best management strategy.


Disclosure of Commercial Interest:
The following authors, contributors, and planners have indicated that they do not have a financial relationship with a commercial organization that may have a direct or indirect interest in the subject matter being presented, or with any commercial organization that has provided funds for the educational activity
  • G. Abbott has nothing to disclose.
  • M. Ahmed has nothing to disclose.
  • L. Ananthakrishnan has nothing to disclose.
  • C. Appleton has nothing to disclose.
  • M. Baerlocher has nothing to disclose.
  • D. Baumgarten has nothing to disclose.
  • R. Beighton has nothing to disclose.
  • D. Bellini has nothing to disclose.
  • D. Bennett has nothing to disclose.
  • S. Bhalla has nothing to disclose.
  • A. Bhavsar has nothing to disclose.
  • J. Brucker has nothing to disclose.
  • B. Carter has nothing to disclose.
  • H. Chandarana has nothing to disclose.
  • C. Chapman has nothing to disclose.
  • J. Coleman has nothing to disclose.
  • J. Courtier has nothing to disclose.
  • M. Edison has nothing to disclose.
  • M. Elezaby has nothing to disclose.
  • R. El-Maraghi has nothing to disclose.
  • J. Erasmus has nothing to disclose.
  • G. Fatterpekar has nothing to disclose.
  • F. Fintelmann has nothing to disclose.
  • E. Flagg has nothing to disclose.
  • A. Galifianakis has nothing to disclose.
  • N. Gandhi has nothing to disclose.
  • W. Gibbs has nothing to disclose.
  • M. Gipson has nothing to disclose.
  • M. Godoy has nothing to disclose.
  • J. Grajo has nothing to disclose.
  • J. Hooker has nothing to disclose.
  • H. Hosseini-nik has nothing to disclose.
  • J. Hussain has nothing to disclose.
  • S. Jolly has nothing to disclose.
  • M. Kater has nothing to disclose.
  • T. Kennedy has nothing to disclose.
  • A. Kielar has nothing to disclose.
  • M. Kransdorf has nothing to disclose.
  • R. Kwee has nothing to disclose.
  • D. Lam has nothing to disclose.
  • S. Lee has nothing to disclose.
  • R. Legha has nothing to disclose.
  • J. Leyendecker has nothing to disclose.
  • A. Li has nothing to disclose.
  • G. LiMarzi has nothing to disclose.
  • B. Majdalany has nothing to disclose.
  • A. Mamidipalli has nothing to disclose.
  • P. Manoharan has nothing to disclose.
  • K. Maturen has nothing to disclose.
  • T. McLoud has nothing to disclose.
  • A. Mileto has nothing to disclose.
  • M. Murphey has nothing to disclose.
  • P. Murphy has nothing to disclose.
  • K. Myers has nothing to disclose.
  • S. Naidu has nothing to disclose.
  • T. Nguyen has nothing to disclose.
  • P. Nikolaidis has nothing to disclose.
  • E. Odisio has nothing to disclose.
  • D. Panicek has nothing to disclose.
  • M. Parisi has nothing to disclose.
  • M. Parsons has nothing to disclose.
  • J. Peterson has nothing to disclose.
  • M. Petranovic has nothing to disclose.
  • C. Pettis has nothing to disclose.
  • H. Rahbar has nothing to disclose.
  • E. Remer has nothing to disclose.
  • K. Scherer has nothing to disclose.
  • D. Schonlau has nothing to disclose.
  • J. Schorge has nothing to disclose.
  • S. Shah has nothing to disclose.
  • A. Sharma has nothing to disclose.
  • D. Shaw has nothing to disclose.
  • R. Sieberg has nothing to disclose.
  • M. Smith has nothing to disclose.
  • B. Spilseth has nothing to disclose.
  • L. States has nothing to disclose.
  • J. Stern-Delfiner has nothing to disclose.
  • J. Sung has nothing to disclose.
  • S. Thipphavong has nothing to disclose.
  • C. Torres has nothing to disclose.
  • N. Valeur has nothing to disclose.
  • S. Verma has nothing to disclose.
  • K. Vo has nothing to disclose.
  • C. Wasyliw has nothing to disclose.
  • D. Wells has nothing to disclose.
  • J. Willat has nothing to disclose.
  • D. Wolfman has nothing to disclose.
  • V. Yaghmai has nothing to disclose.
  • M. Yao has nothing to disclose.
  • D. Yoo has nothing to disclose.
  • N. Zakhari has nothing to disclose.

The following faculty and authors have indicated they have a disclosure of commercial interest:
  • L. Bancroft is recipient of speaker honoraria from Harvard University, Radiology International and New York University.
  • L. Fayad was a GERRAF fellow from 2008-2010 and is recipient of salary support and project funds from Siemens Healthcare.
  • R. Gupta is a consultant and on the speakers bureau for Bayer Pharma AG. He is also a consultant for Invivo Corp.
  • K. Jhaveri is recipient of speaker honoraria from Siemens Canada and research support from Bayer Canada.
  • D. Kim is co-owner of VirtuoCTC. He serves on medical advisory board of Digital Art Forms, Inc. He is also recipient of speaker honorarium from Viatronix, Inc.
  • J. Ko is recipient of honorarium from Siemens AG.
  • M. Law serves on the medical advisory board for Guerbet, Bracco Diagnostics, and Prism Clinical Imaging. She is recipient of honorarium from Toshiba.
  • M. Lubner is recipient of grant funding from Neuwave medical, GE Healthcare, and Philips.
  • J. Leung serves on the speaker’s bureau and medical advisory board for Hologic, Inc.
  • R. Nelson is recipient of honoraria from GE Healthcare, Guerbet and Nemoto Kyorindo, Ltd. He is recipient of research grant from Bracco Diagnostics and Nemoto Kyorindo, Ltd. He is recipient of book royalty from Lippincott-William and Wilkins.
  • P. Pickhardt is co-owner of VirtuoCTC. He has stock ownership of Cellectar Biosciences. He is GI section editor for the AJR. He is a consultant for Check-Cap and received research support from Philips.
  • J. Reid is recipient of book royalty from Oxford University Press.
  • C. Sirlin is recipient of research grant from GE Healthcare, Siemens Healthcare, Guerbet and Pfizer. He has a research contract with Bayer, Genzyme, Gilead, Isis, Janssen, Sanofi, Synageva and Takeda. He is recipient of honoraria from VirtualScopics.
  • F. Sodagari is recipient of educational grant from Siemens Healthcare.
  • E. Tamm is recipient of research support from GE Healthcare.
  • C. Wu is recipient of book royalty from Elsevier.
C. Glastonbury Glastonbury is an investor, author, and recipient of dividends and royalty from Amirsys, Inc.
  • C. Torres has nothing to disclose
  • S. Symons has nothing to disclose
  • A. Vagal has nothing to disclose
  • L. Bancroft is the recipient of speaker fees from Radiology International and from IDKD.
  • C. Chin has nothing to disclose
  • D. Wessell has nothing to disclose
  • J. Wu has nothing to disclose
  • V. Ho-Fung has nothing to disclose
  • J. Reid has nothing to disclose
  • E. Lee has nothing to disclose
  • S. Anupindi has nothing to disclose
  • K. Fink receives salary support from Bayer Healthcare, Guerbet, LLC and Bracco Diagnostics, Inc.
  • L. Fordham has nothing to disclose
  • E. England has nothing to disclose
  • A. Kielar has nothing to disclose
  • D. Yoo received a consulting fee from Endocyte
  • D. Litmanovich is a principal investigator and recipient of research grants from Radiology Society of North America, Association of University Radiologists, Association of Program Directors in Radiology, and Society of Chairmen of Academic Radiology Departments. She also received a research grant from Society of Thoracic Radiology.
  • S. Patel has nothing to disclose
  • C. Raptis has nothing to disclose
  • C. Menias has nothing to disclose
  • B. Siewert has nothing to disclose
  • S. Anderson has nothing to disclose
  • S. Bhatt has nothing to disclose
  • S. Allison has nothing to disclose
  • D. Baumgarten has nothing to disclose
  • K. Richman has nothing to disclose
  • P. Glanc has nothing to disclose
  • M. Smith is the recipient of research support from Bayer Pharmaceuticals, Bracco Diagnostics, Inc., and GE Healthcare.
  • T. Angtuaco has nothing to disclose
  • P. Pickhardt has nothing to disclose
  • N. Dahiya has nothing to disclose
  • M. Ahmed has nothing to disclose
  • M. Lubner has nothing to disclose
  • K. Hong has nothing to disclose
  • I. Brennan has nothing to disclose
  • K. Sandrasegaran is a consultant and on the Speakers Bureau for Repligen Corp.
  • A. Harris has nothing to disclose
  • T. Weber has nothing to disclose
  • M. Blake has nothing to disclose


  • Member Price:
    $80.00
    NonMember Price:
    $250.00